Page 1

Corporate | 30 September 2026 09:04 Gerresheimer AG / Key word ( s ) : Half Year Results Gerresheimer Reports Q2 2026 > 50 % up in Adj . EBITDA Quarter on Quarter 30.09.2026 / 09 : 04 CET / CEST The issuer is solely responsible for the content of this announcement . Gerresheimer Reports Q2 2026 > 50 % up in Adj . EBITDA Quarter on Quarter . Preliminary Q2 Results : Revenue EUR 578m ( + EUR 55m from Q1 ) , adjusted EBITDA EUR 102m ( + EUR 35m from Q1 ) • • Stronger second half of 2026 expected Preparations for closing of Centor sale are in final stages Düsseldorf , September 30 , 2026. Gerresheimer , an innovative system and solution provider and global partner to the pharma , biotech , and cosmetics industries , today published preliminary results for the second quarter of 2026 and the first half of 2026. Revenue and adjusted EBITDA rose significantly in the second quarter of 2026 compared to the first quarter of 2026 , but remained below the results of the same quarter last year . In the first half of 2026 , Gerresheimer generated total revenues of EUR 1.10 billion according to preliminary figures and excluding adjustments for the business units currently in the sales process ( first half of 2025 : EUR 1.14 billion , adjusted ) , of which EUR 578 million was generated in the second quarter of 2026 ( Q2 2025 : EUR 614 million , adjusted ) . Adjusted EBITDA reached EUR 168 million ( first half of 2025 : EUR 224 million , adjusted ) , of which the second quarter contributed approximately EUR 102 million ( Q2 2025 : EUR 126 million , adjusted ) . The adjusted EBITDA margin improved by 5.0 percentage points in the second quarter of 2026 compared to the first quarter of 2026 , reaching 17.6 % . Overall , the adjusted EBITDA margin for the first half of 2026 was approximately 15.3 % due to the subdued first quarter ( first half of 2025 : 19.6 % , adjusted ) . Revenue performance in the first half of 2026 was positively influenced primarily by the Containment & Delivery Systems division , which saw stronger demand for drug delivery devices . For the current financial year 2026 , Gerresheimer expects a stronger second half with improved earnings and a significantly improved financial situation . The sale of Centor is proceeding according to plan and the transaction is expected to close